News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV. View on euronews ...

Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...